BMRN - BioMarin Pharmaceutical Inc.
| Previous Close | 86.06 |
| Open | 85.11 |
| Bid | 84.40 x 900 |
| Ask | 95.00 x 1100 |
| Day's Range | 83.02 - 87.25 |
| 52 Week Range | 62.88 - 97.10 |
| Volume | 1,777,374 |
| Avg. Volume | 1,600,393 |
| Market Cap | 15.152B |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.13 |
| Earnings Date | Apr 22, 2020 - Apr 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 117.64 |
- Zacks
BioMarin (BMRN) Down 8% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Investopedia
The Top 10 Biotechnology Companies
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more.
- Thomson Reuters StreetEvents
Edited Transcript of BMRN earnings conference call or presentation 26-Feb-20 9:30pm GMT
Q4 2019 Biomarin Pharmaceutical Inc Earnings Call
- Insider Monkey
Is BioMarin Pharmaceutical Inc. (BMRN) Going to Burn These Hedge Funds?
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published this article and predicted that US stocks will go down by at least 20% in the next 3-6 months. We also told you to short the market ETFs and buy long-term bonds. Investors who agreed with […]
- PR Newswire
BioMarin's Brinda Balakrishnan, M.D., Ph.D., Honored with 2020 "40 Under 40" Award from the San Francisco Business Times
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Brinda Balakrishnan, M.D., Ph.D., has been named to the San Francisco Business Times 2020 "40 Under 40" list. Now in its ninth year, the San Francisco Business Times "40 Under 40" list highlights the Bay Area's best and brightest young business and community leaders. Dr. Balakrishnan is the only woman biotech leader to be included in this year's list.
- Simply Wall St.
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 26% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of BioMarin...
- Zacks
BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus
BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.
- Zacks
Stock Market News for Feb 27, 2020
U.S. equities disappointed on Wednesday, as most of the major benchmarks ended mostly lower.
- Zacks
BioMarin Pharmaceutical (BMRN) Q4 Earnings Top Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 19.05% and -1.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- MoneyShow
Biomarin- Gene Therapy and Hemophilia
Biomarin (BMRN) just recently announced that the FDA has accepted for Priority Review the BLA for ValRox (valoctocogene roxaparvovec) for adults with hemophilia A, notes biotech expert John McCamant, editor of The Medical Technology Stock Letter.
- Zacks
BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?
Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.
- Zacks
BioMarin (BMRN) Catches Eye: Stock Jumps 6.1%
BioMarin (BMRN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Benzinga
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
- PR Newswire
BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) to the FDA for its investigational AAV5 gene therapy, valoctocogene roxaparvovec, for adults with hemophilia A. This acceptance by the FDA marks the first marketing application accepted for a gene therapy product for any type of hemophilia in the United States.
- MarketWatch
Health-care stocks hinge on presidential politics — and they’re now looking favorable
Investors have become more comfortable with the likes of UnitedHealth as Elizabeth Warren’s political fortunes have soured.
- Zacks
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GuruFocus.com
Frank Sands' Firm Sells 4 Stocks in 4th Quarter
Sands Capital Management exits positions in Biomarin, Palo Alto Networks Continue reading...
- PR Newswire
BioMarin to Participate in Two Upcoming Investor Conferences
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the 9th Annual Leerink Partners Global Healthcare Conference on February 26, 2020 at 10:00am ET in New York City and the Cowen and Company 40th Annual Health Care Conference on March 3, 2020 at 10:40am ET in Boston. To access the events that are accessible by live webcasts, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following each event.
- American City Business Journals
Drug makers tap genetic test to save kids with seizures
As more drug companies subsidize the cost of the genetic test, more patients can be tested and, potentially, matched to the companies' drugs.
- GuruFocus.com
Goldman Sachs Sets BioMarin Target 75% Above Current Price
The gene therapy company is expected to introduce hemophilia drug that is projected to generate revenue of $1.2 billion by 2024 Continue reading...
- Benzinga
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...
- PR Newswire
BioMarin Announces CFO Succession
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced the transition of Executive Vice President and Chief Financial Officer Dan Spiegelman. Mr. Spiegelman will remain as an employee and senior advisor until September 1, 2020 to assist with the transition. After that, he plans to pursue other interests and spend more time with family. Brian R. Mueller, Senior Vice President, Finance and Chief Accounting Officer, has assumed the role of acting Chief Financial Officer. The Company is initiating an internal and external search for the role of Chief Financial Officer.
- GuruFocus.com
Andreas Halvorsen Trims Adaptive Biotechnologies Stake
The immune-driven biotech company went public last June Continue reading...
- PR Newswire
BioMarin to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, February 26 at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 26, at 4:30 p.m. ET to discuss fourth quarter and full year 2019 financial results and provide a general business update.
- Investopedia
3 Biotech Stocks Nearing Support
Pricing concerns have resurfaced among biotech stocks this month. The recent pullback could offer a buying opportunity.
